Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development of Olaparib for BRCA-Deficient Recurrent Epithelial Ovarian Cancer

14 Jul 2015

Abstract excerpt

The FDA approval of the PARP inhibitor olaparib for fourth-line therapy of germline BRCA1/2-mutated ovarian cancer represents the first registered indication for this class of drugs in any disease. PARP is a family of proteins involved in the repair of single-strand DNA breaks. High-grade serous ovarian carcinomas with BRCA deficiencies may be particularly vulnerable to both direct and indirect effects of PARP...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA gene mutations in cancer
Share to Ovarian cancer diagnosis and treatment
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26169965
DOI: 10.1158/1078-0432.ccr-15-0088

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development of Olaparib for BRCA-Deficient Recurrent Epithelial Ovarian CancerPMID 26169965Read ↗

Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy.Semantic proximity Read ↗

Olaparib for the treatment of relapsed ovarian cancer with a BRCA1/2 mutation.Semantic proximity Read ↗

Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancerSemantic proximity Read ↗

Olaparib in the management of ovarian cancerSemantic proximity Read ↗

PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions.Semantic proximity Read ↗

The safety and efficacy of olaparib therapy in patients with relapsed ovarian cancer.Semantic proximity Read ↗

Olaparib and advanced ovarian cancer: Summary of the past and looking into the futureSemantic proximity Read ↗

PARP Inhibitors for Ovarian Cancer: Current Indications, Future Combinations, and Novel Assets in Development to Target DNA Damage RepairSemantic proximity Read ↗

PARP inhibitors in ovarian cancer.Semantic proximity Read ↗

PARP Inhibitors in Ovarian CancerSemantic proximity Read ↗

PARP Inhibitors in Ovarian Cancer: A ReviewSemantic proximity Read ↗

PARP inhibitors: Clinical utility and possibilities of overcoming resistanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.